Investor webinar 5 September 2017
1, September, 2017
Admedus Limited (ASX: AHZ) held an investor webinar on 5 September, 2017 to discuss the results of the Company’s Preliminary Final Report (Appendix 4E) for the year ended 30 June 2017. Admedus CEO Wayne Paterson will provide a review of the Company’s year-end performance as well as operational and business highlights.
Admedus announces exclusive supply agreement with 4C Medical
31, August, 2017
Admedus Limited is pleased to announce that it has entered an exclusive supply agreement with 4C Medical Technologies, Inc. (4C Medical), a Minnesota-based developer of minimally invasive therapies for structural heart disease. Read more here.
Sponsorship supports kids with heart disease
15, August, 2017
Admedus Ltd is proud to announce a six-month $20k sponsorship of the HeartKids Education Program which provides vital resources for families of children living with congenital/childhood heart disease. In Australia, congenital/childhood heart disease is the leading cause of death for children under a year old and nearly three thousand babies are born with a heart […]
Long-term study indicates no calcification with CardioCel after eight years
22, August, 2016
Long-term data from a Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel shows that all patients continue to progress well, with no sign of calcification or need for repeat procedures.
Admedus shares rise on hospital infusion pump supply deal with Arcomed
25, May, 2016
Admedus said today it won a supply contract with the new Royal Adelaide Hospital for the installation of the Arcomed chroma infusion pump systems. The supply tender includes ongoing technical and clinical support as well as consumable products for the systems over the next 5 years.
Admedus Wins 2016 Australian Manufacturer of the Year Award
14, May, 2016
After triumphing in the Most Innovative category, Admedus also took out the night’s biggest award ‘Manufacturer of the Year’. In August 2014 Admedus opened its state-of-the-art bio-manufacturing facility in Malaga, WA, and has experienced huge success in exporting its bio-scaffold regenerative medicine product, CardioCel, since then.